Based on cluster analyses, different phenotypes have been recognised in asthma and the age of onset has been found to be a key factor distinguishing these phenotypes [4, 5] . Early-onset asthma has typically been associated with atopy and allergies, and characterised by a good response to inhaled corticosteroids and relatively high remission rate [4, 5] . Adult-onset asthma, on the other hand, has received less attention. Recent studies have suggested adult-onset asthma to have lower remission rates [5, 6] , more rapid loss of lung function [5] and poorer prognosis [6, 7] . In a recent study of age-specific incidence of new asthma diagnoses in Finland, it was reported that most diagnoses of persistent asthma are actually made in adulthood [8] . In a US-based study, the adult-onset phenotype was reported to dominate especially among women [9] . Moreover, in a clinical cohort of consecutive, new adult-onset asthma patients (Seinäjoki Adult Asthma Study [6, 10] ), the mean±SD age of asthma onset was found to be 46±13.7 years, which is substantially higher than the suggested limit [6, 10] . These findings raise a question of whether the age limit of 40 years is actually applicable to real-life clinical work.
In Finland, every patient with persistent asthma is entitled to asthma reimbursement by the Social Insurance Institution of Finland (SII). The number of new asthma reimbursements reflects the number of novel asthma diagnoses made. We obtained numbers of patients from the SII and evaluated the age at which the reimbursement was obtained in Finland during 2012-2013, in order to evaluate whether diagnoses of persistent asthma were made either before or after 40 years of age. Data acquisition and calculation of novel asthma medication reimbursements were made as previously described [8] .
In 2012-2013, in Finland ( population 5.4 million), 26 281 new patients were entitled to special reimbursement for their asthma medication (13 941 females and 12 340 males). Of these, only 12 095 (46.0%) persons belonged to age group 0-39 years, indicating that a majority (54.0%) of new patients who obtained special asthma medication reimbursement were older than 40 years (figure 1). More than half (57.9%) of females were ⩾40 years; in contrast, 50.5% of men obtained asthma reimbursement before their 40th birthday (figure 1). In conclusion, these results further suggest that most asthma is diagnosed after @ERSpublications The suggested asthma-onset age limit of 40 as a criterion for ACOS may lead to severe underdiagnosis of ACOS http://ow.ly/rVSk30ckrOq The perception of asthma being merely a childhood-onset disease persists; however, the adult-onset phenotype of asthma has been identified in several studies and is recognised by guidelines. There is already evidence that a majority of persistent asthma may actually start in adulthood [8, 9], making it necessary to take patients with adult-onset asthma into consideration when the starting age of asthma is recommended as a diagnostic criterion. In order to obtain a diagnosis, and administer good and increasingly personalised therapy to our ACOS patients, the diagnostics must be accurate and sensitive regardless of sex, age and smoking status. Using the suggested age limit of 40 years as a criterion for ACOS may lead to severe underdiagnosis of ACOS when patients with asthma onset after 40 years of age are not included. This especially concerns women. Thus, we propose that the suggested age limit of asthma onset in the criteria of ACOS should be reconsidered. 
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From the authors:
M. Tommola and colleagues raise an important and hotly debated diagnostic criterion of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): an age threshold of 40 years for the asthma component of ACOS. We agree with their comment that asthma can develop later in life and these patients may respond well to inhaled corticosteroids and novel biologics, similar to those with childhood-onset asthma [1] . Thus, in the roundtable consensus report [2] , we suggested that the asthma component of ACOS could be fulfilled by a clinical diagnosis of asthma before age 40 years or in those without a clinical diagnosis of asthma before 40 years by demonstrating an improvement in forced expiratory volume in 1 s (FEV1) of ⩾400 mL following short-acting β 2 -agonist therapy. While a significant bronchodilatory response (BDR) is a common feature in both asthma and chronic obstructive pulmonary disease (COPD) [3] , it is very unusual for COPD patients to demonstrate a BDR of ⩾400 mL in FEV1 without a concomitant diagnosis of asthma [4] . To further improve the specificity of the asthma component of ACOS, we also suggested that in addition to all three major criteria, patients fulfil at least one of the three minor criteria: 1) a history of atopy or allergic rhinitis; 2) a BDR of ⩾200 mL in FEV1 on two separate visits; or 3) peripheral eosinophil count of ⩾300 cells per μL. While none of these criteria has been validated in ACOS, we believe that these criteria are clinically workable and may be useful in identifying patients with asthma with reasonable precision. Future work will be needed to refine these criteria based on high-grade data. 
